MARC SCHWABISH, PHD

Marc Schwabish has a diverse background spanning Biopharma, Finance, Consulting, and Science. He was previously Head of US Pharma Business Development and Licensing at Bayer. He worked across Bayer’s therapeutic areas, focusing on late stage development opportunities, commercialized assets, and innovative partnerships. Prior to Bayer, Dr. Schwabish had both business development and alliance management responsibilities at Eisai. His deal experience at Eisai covered a range of diseases and stages of assets, from early research technologies through commercialized therapeutics. Dr. Schwabish previously worked in Healthcare Investment Banking at RBS (Leverage Finance and M&A), Pharma Strategy Consulting at Leerink Swann (now Guidehouse), and in research and development and product management at other pharmaceutical and biotechnology companies. He has closed over 25 transactions across anti-infectives, cardiology, gastrointestinal, metabolism, neurology, oncology, thrombosis, and women’s healthcare.

Dr. Schwabish holds a PhD in Biochemistry and Molecular Pharmacology from Harvard and a BS in Biology from Cornell.